

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

**ANNOUNCEMENT IN RELATION TO
(1) APPOINTMENT OF EXECUTIVE DIRECTOR
AND
(2) RESIGNATION OF EXECUTIVE DIRECTOR**

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of China Shineway Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Liu Tiejun (“**Mr. Liu**”) has been appointed as executive director of the Company with effect from 1 November 2022.

Mr. Liu, aged 48, joined the Group in 1999 and was appointed as vice president of Shineway Pharmaceutical Group Limited (“**Shineway Pharmaceutical**”) (an indirect wholly-owned subsidiary of the Company) on 16 May 2013. Mr. Liu is qualified as a senior engineer and is a certified pharmacist. He graduated from Hebei Medical University in 1999 with a bachelor’s degree in pharmacy. Mr. Liu is a member of the China Association of Chinese Medicine (Chinese Medicine Branch) and a deputy director of the National and Local United Engineering Laboratory for the Development Technology of New Chinese Medicine Injection. He has received an award of “Model Worker of Hebei Province” * (「河北省勞動模範」) by the People’s Government of Hebei Province. Mr. Liu is currently the rotating president and the legal representative of Shineway Pharmaceutical, being responsible for overseeing the Group’s production technology management with more than 20 years of experience.

Mr. Liu did not hold any directorships in the last three years in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas. Save as disclosed above, Mr. Liu does not hold any position with the Company or other members of the Group. As at the date of this announcement, Mr. Liu (i) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company; and (ii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company will enter into an appointment letter with Mr. Liu for a term of two years commencing from 1 November 2022 and is subject to retirement and re-election provisions in the articles of association of the Company. Mr. Liu will be entitled to a total annual remuneration of RMB1,000,000 from the Group. He is eligible to receive performance

related discretionary bonus of a sum to be determined by the Board. The emoluments of Mr. Liu were determined on the basis of Mr. Liu's experience, level of responsibilities within the Group and the current market situation.

Save as disclosed above, Mr. Liu confirmed that there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and the Company is not aware of any other matters in relation to appointment of Mr. Liu that need to be brought to the attention of shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Liu to join the Company.

RESIGNATION OF EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Chen Zhong (“**Mr. Chen**”) has tendered his resignation as an executive director of the Company with effect from 1 November 2022, due to his intention to devote more time to pursue his personal interests.

Mr. Chen has confirmed that he has no disagreement with the Board and that he is not aware of any matters in relation to his resignation as an executive director of the Company that need to be brought to the attention of the shareholders of the Company. The Board would like to express its sincere gratitude to Mr. Chen for his valuable contributions to the Company during his tenure of service.

By Order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 31 October 2022

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Mr. Liu Shun Fai and Mr. Yew Yat On.

** For identification purpose only*